Date of Award
Selective Evidence-Based Medicine Review
Master of Science in Health Sciences - Physician Assistant
Physician Assistant Studies
John Cavenagh, MBA, PhD, PA-C
Objective: The objective of the selective EBM review is to determine whether or not Rabeprazole is a safe treatment for GERD in children less than sixteen years old.
Study Design: Review of three randomized controlled studies. All three studies were published in English between 2007-2013.
Data Sources: Three randomized, un-blinded, controlled studies found using Medline and PubMed
Outcomes Measured: Each trial measured the adverse events that occurred with the use of Rabeprazole for the treatment of GERD in children less than sixteen years of age. This was done by using subjective reporting of treatment-emergent adverse events (TEAE’s). Differences in the frequency of Treatment Emergent Signs and Symptoms (TESS) between the two treatment groups analyzed using the Fischer exact test and/or an appropriate nonparametric procedure.
Results: Three un-blinded RCT’s were included in this review and it was found that Rabeprazole did not lead to any significant life-threatening treatment-emergent adverse events (TEAE’s) in patients less than sixteen years of age. The most common adverse events were headache, nausea, cough, vomiting, abdominal pain, and diarrhea.
Conclusions: Based on these three trials, Rabeprazole is a safe treatment for GERD in children less than sixteen years of age. Each study showed a significant improvement of symptoms without any serious side effects when using Rabeprazole.
Applegarth, Sarah, "Is Rabeprazole A Safe Treatment for Gastroesophageal Reflux Disease in Children Ages 1-16 years?" (2015). PCOM Physician Assistant Studies Student Scholarship. 206.